Market cap
$46 Mln
Recently Viewed
Clear AllMarket cap
$46 Mln
Revenue (TTM)
$5 Mln
P/E Ratio
--
P/B Ratio
3.6
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.8
Debt to Equity
0
Book Value
$--
EPS
$-0.9
Face value
--
Shares outstanding
26,305,295
CFO
$-82.60 Mln
EBITDA
$-140.86 Mln
Net Profit
$-145.71 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
LAVA Therapeutics NV (LVTX)
| 83.0 | 8.1 | 12.3 | 8.8 | -32.9 | -- | -- |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
LAVA Therapeutics NV (LVTX)
| -54.9 | -36.4 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
LAVA Therapeutics NV (LVTX)
|
1.7 | 45.8 | 5.0 | -23.3 | -442.3 | -121 | -- | 3.6 |
| 4.1 | 1,698.8 | 4.1 | -660.1 | -2,789.5 | -390.4 | -- | 7.6 | |
| 90.0 | 6,826.3 | 51.2 | -334.9 | -636.8 | -53.3 | -- | 8.8 | |
| 34.0 | 7,824.7 | 2,090.0 | 424.9 | 25.0 | 11.6 | 18.6 | 2.1 | |
| 20.5 | 1,127.4 | 16.1 | -199.0 | -975.8 | -207.1 | -- | 5.7 |
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the... potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands. Read more
CEO, President & Executive Director
Mr. Stephen Allen Hurly M.B.A., M.Sc.
CEO, President & Executive Director
Mr. Stephen Allen Hurly M.B.A., M.Sc.
Headquarters
Utrecht
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of LAVA Therapeutics NV (LVTX) is $1.74 (NASDAQ) as of 28-Nov-2025 09:30 EDT. LAVA Therapeutics NV (LVTX) has given a return of -32.86% in the last 3 years.
Since, TTM earnings of LAVA Therapeutics NV (LVTX) is negative, P/E ratio is not available.
The P/B ratio of LAVA Therapeutics NV (LVTX) is 3.61 times as on 28-Nov-2025, a 36 discount to its peers’ median range of 5.67 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.02
|
0.92
|
|
2023
|
-1.01
|
0.83
|
|
2022
|
-2.84
|
1.05
|
|
2021
|
-3.13
|
1.20
|
|
2020
|
--
|
--
|
The 52-week high and low of LAVA Therapeutics NV (LVTX) are Rs 2.00 and Rs 0.85 as of 30-Apr-2026.
LAVA Therapeutics NV (LVTX) has a market capitalisation of $ 46 Mln as on 28-Nov-2025. As per SEBI classification, it is a Small Cap company.
Before investing in LAVA Therapeutics NV (LVTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.